GlassScriptPhysician profile
Robert S Tausend
NPI 1407839269
$8,491.84
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,660 · 2020: $2,810 · 2022: $22.02.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $2,492.42 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $1,074.37 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $985.79 | 2019-2022 | |
| Galderma Laboratories, L.P. | $977.22 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $361.61 | 2019-2020 | |
| Almirall LLC | $309.15 | 2019 | |
| Pfizer INC. | $275.28 | 2019-2020 | |
| Abbvie INC. | $262.90 | 2019-2020 | |
| Ucb, INC. | $239.13 | 2020 | |
| Lilly USA, LLC | $219.35 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $175.26 | 2020 | |
| Epi Health, LLC | $118.97 | 2019-2020 | |
| Celgene Corporation | $117.22 | 2019 | |
| Leo Pharma INC. | $116.97 | 2019-2020 | |
| Amgen INC. | $111.01 | 2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $98.03 | 2019 | |
| Encore Dermatology INC. | $65.93 | 2019-2020 | |
| Vyne Pharmaceuticals INC. | $62.68 | 2020 | |
| Aclaris Therapeutics, INC. | $53.26 | 2019 | |
| Promius Pharma LLC | $47.55 | 2019 | |
| Dermira, INC. | $46.27 | 2019-2020 | |
| Mission Pharmacal Company | $44.89 | 2019-2020 | |
| Genentech USA, INC. | $40.49 | 2020 | |
| Janssen Biotech, INC. | $36.78 | 2020 | |
| Mylan Pharmaceuticals INC. | $30.34 | 2019 | |
| Journey Medical Corporation | $23.81 | 2019 | |
| Dusa Pharmaceuticals, INC. | $22.94 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $20.38 | 2019 | |
| Stemline Therapeutics INC. | $20.35 | 2020 | |
| Pierre Fabre Pharmaceuticals, INC. | $16.56 | 2019 | |
| Glenmark Therapeutics INC. | $13.00 | 2019 | |
| Melinta Therapeutics, LLC | $11.93 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Tausend listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.